GENENTECH, INC. $500,000,000, 4.40% Senior Notes due 2010 $1,000,000,000, 4.75% Senior Notes due 2015 $500,000,000, 5.25% Senior Notes due 2035 Purchase AgreementGenentech Inc • November 4th, 2005 • Pharmaceutical preparations • New York
Genentech, Inc., a corporation organized under the laws of Delaware (the "Company"), proposes to issue and sell to the several parties named in Schedule I hereto (the "Initial Purchasers"), for whom you (the "Representatives") are acting as representatives, $500,000,000 aggregate principal amount of its 4.40% Senior Notes due 2010 (the "2010 Notes"), $1,000,000,000 aggregate principal amount of its 4.75% Senior Notes due 2015 (the "2015 Notes") and $500,000,000 aggregate principal amount of its 5.25% Senior Notes due 2035 (the "2035 Notes," and together with the 2010 Notes and the 2035 Notes, the "Securities"). The Securities are to be issued under an indenture, to be dated as of the Closing Date, between the Company and The Bank of New York Trust Company, N.A., as trustee (the "Trustee"), as supplemented by an Officers' Certificate to be dated as of the Closing Date (as supplemented, the "Indenture"). Holders of the Securities will have the benefit of a registration rights agreement (
TOLL MANUFACTURING AGREEMENT By and Between WYETH, Acting through its Wyeth Pharmaceuticals Division and GENENTECH, INC.Toll Manufacturing Agreement • November 4th, 2005 • Genentech Inc • Pharmaceutical preparations • Delaware
This TOLL MANUFACTURING AGREEMENT (the "Agreement") is made effective as of September 15, 2004 (the "Effective Date"), by and between Wyeth, a Delaware corporation acting through its Wyeth Pharmaceuticals Division having its principal place of business at Five Giralda Farms, Madison, New Jersey 07940 ("Wyeth"), and Genentech, Inc., a Delaware corporation, having its principal place of business at One DNA Way, South San Francisco, California 94080 ("Genentech"). Wyeth and Genentech may each be referred to herein individually as a "Party" and collectively as the "Parties."
MANUFACTURING AND SUPPLY AGREEMENT Between GENENTECH, INC. and LONZA BIOLOGICS, INC. Dated December 7, 2003Manufacturing and Supply Agreement • November 4th, 2005 • Genentech Inc • Pharmaceutical preparations • California
Genentech markets and sells a certain proprietary biological pharmaceutical product known as Rituxan. Genentech desires to obtain additional supply of commercial quantities of Rituxan bulk drug substance. Lonza has the experience and expertise necessary to perform the manufacturing and related services needed to supply Rituxan bulk drug substance, and Lonza owns a facility that, with some modifications, could be suitable for production of commercial quantities of Rituxan bulk drug substance.
